Pharmx Technologies (Australia) Insiders
| PHX Stock | 0.09 0.01 6.25% |
Pharmx Technologies employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Pharmx Technologies' management performance can provide insight into the firm performance.
| Nick England Chairman Interim Chairman |
Pharmx |
Pharmx Technologies Management Team Effectiveness
Change To Liabilities is likely to gain to about 9.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9 M in 2025. Pharmx Technologies' management efficiency ratios could be used to measure how well Pharmx Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to gain to about 722.7 M in 2025, despite the fact that Net Loss is likely to grow to (1.5 M).
Pharmx Technologies Workforce Comparison
Pharmx Technologies is currently under evaluation in number of employees category among its peers. The total workforce of Information Technology industry is at this time estimated at about 1,098. Pharmx Technologies adds roughly 0.0 in number of employees claiming only tiny portion of equities under Information Technology industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.11 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.11. Pharmx Technologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pharmx Technologies Price Series Summation is a cross summation of Pharmx Technologies price series and its benchmark/peer.
Pharmx Technologies Notable Stakeholders
A Pharmx Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pharmx Technologies often face trade-offs trying to please all of them. Pharmx Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pharmx Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Nick England | Interim Chairman | Profile | |
| Tom Culver | Chief Officer | Profile | |
| Zoe Hillier | Chief Officer | Profile | |
| Christopher Fernandes | Company Secretary | Profile | |
| James Nevile | Chief Officer | Profile | |
| Eryl Baron | Company Secretary | Profile | |
| Sally McDow | Company Secretary | Profile |
About Pharmx Technologies Management Performance
The success or failure of an entity such as Pharmx Technologies often depends on how effective the management is. Pharmx Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pharmx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pharmx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Pharmx Technologies is entity of Australia. It is traded as Stock on AU exchange.
Please note, the imprecision that can be found in Pharmx Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharmx Technologies. Check Pharmx Technologies' Beneish M Score to see the likelihood of Pharmx Technologies' management manipulating its earnings.
Pharmx Technologies Workforce Analysis
Traditionally, organizations such as Pharmx Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pharmx Technologies within its industry.Pharmx Technologies Manpower Efficiency
Return on Pharmx Technologies Manpower
| Revenue Per Employee | 968.7K | |
| Revenue Per Executive | 968.7K | |
| Net Loss Per Employee | 252.7K | |
| Net Loss Per Executive | 252.7K | |
| Working Capital Per Employee | 631.3K | |
| Working Capital Per Executive | 631.3K |
Additional Tools for Pharmx Stock Analysis
When running Pharmx Technologies' price analysis, check to measure Pharmx Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmx Technologies is operating at the current time. Most of Pharmx Technologies' value examination focuses on studying past and present price action to predict the probability of Pharmx Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmx Technologies' price. Additionally, you may evaluate how the addition of Pharmx Technologies to your portfolios can decrease your overall portfolio volatility.